Non-small cell lung cancer

- Independent Prognostic Factors of Survival in Elderly Patients Undergoing Surgery for Non-small Cell Lung Cancer Brain Metastases: Assessing Surgical Eligibility
- Elucidation of lorlatinib toxicity mechanisms through GC-MS-based metabolomics
- Re-irradiation for local recurrence after definitive stereotactic body radiotherapy for early-stage non-small cell lung cancer
- Corrigendum to "TP53 and EGFR amplification are negative predictors of overall survival in patients diagnosed with non-small cell lung cancer with brain metastases" [Heliyon Volume 10, Issue 16, August 2024, Article e36532]
- NRF2 pathway activation predicts poor prognosis in lung cancer: a cautionary note on antioxidant interventions
- Solitary brain metastasis mimicking meningioma as the initial presentation of concurrent pulmonary and breast sarcomatoid carcinoma in a male patient: A rare entity with literature review
- Prognostic Impact of Tumor Solid Components in Stereotactic Body Radiotherapy for Clinical Stage Tis-1N0M0 Lung Cancer
- Management outcomes for biopsy-proven radiation necrosis in patients with brain metastases in the era of immune-checkpoint blockade

---

Non-small-cell lung cancer (NSCLC) is any type of epithelial lung cancer other than Small-cell lung cancer (SCLC).

Includes: adenocarcinoma (the most common NSCLC), large cell, squamous cell, bronchoalveolar.

Lung cancer continues to be a leading cause of cancer-related death worldwide, with non-Small-cell lung cancer (NSCLC) accounting for more than 80% of lung cancer cases.

Epidemiology

Lung cancer is the leading cause of cancer mortality worldwide, accounting for 1.38 million annual deaths, representing 18.2% of total deaths from cancer [1].

Non-Small-cell lung cancer (NSCLC) account for more than 80% of lung cancer cases.

Among those, approximately 7.4% of non-Small-cell lung cancer (NSCLC) patients will have brain metastases (BM) at presentation [2] , and between 20–40% of Non-Small-cell lung cancer (NSCLC) patients will develop intracranial metastases [3] [4].

Classification

see Non-Small-cell lung cancer classification.

Diagnosis

Non-Small-cell lung cancer Diagnosis.

Complications

Non-Small-cell lung cancer metastases

Non-Small cell lung cancer metastases

Treatment

see Non-Small cell lung cancer treatment.

Outcome

see Non-Small cell lung cancer outcome.

Case series

Non-Small-cell lung cancer case series.

1)
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):134. PubMed PMID: 21296855.
2)
Schuette W. Treatment of brain metastases from lung cancer: chemotherapy. Lung Cancer. 2004 Aug;45 Suppl 2:S253-7. Review. PubMed PMID: 15552807.
3)
Brower JV, Robins HI. Erlotinib for the treatment of brain metastases in non-Small-cell lung cancer. Expert Opin Pharmacother. 2016;17(7):1013-21. doi: 10.1517/14656566.2016.1165206. Epub 2016 Mar 30. Review. PubMed PMID: 26967582.
4)
Zhao J, Chen M, Zhong W, Zhang L, Li L, Xiao Y, Nie L, Hu P, Wang M. Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma. Clin Lung Cancer. 2013 Mar;14(2):188-93. doi: 10.1016/j.cllc.2012.06.004. Epub 2012 Jul 28. PubMed PMID: 22846582.